Procyclidine

From Wikipedia, the free encyclopedia

Template:Short description Script error: No such module "Distinguish". Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Procyclidine
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa605037
Routes of
administration
By mouth, im, iv
ATC codePage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Protein binding~100%-albumin
Elimination half-life~12 h
Identifiers
  • 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-yl-propan-1-ol hydrochloride
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC19H30ClNO
Molar mass323.90 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Procyclidine is an anticholinergic drug principally used for the treatment of drug-induced parkinsonism, akathisia and acute dystonia, Parkinson's disease, and idiopathic or secondary dystonia.

Medical uses

It is used in patients with parkinsonism and akathisia, and to reduce the side effects of antipsychotic treatment given for schizophrenia. Procyclidine is also a second-line drug for the treatment of Parkinson's disease. It improves tremor but not rigidity or bradykinesia.

Procyclidine is also sometimes used for the treatment of dystonia (but not tardive dyskinesia), a rare disorder that causes abnormal muscle contraction, resulting in twisting postures of limbs, trunk, or face.

Side effects

Side effects include nausea, constipation, urinary retention, blurred vision, anxiety, cognitive impairment, confusion, dizziness, gingivitis, hallucination, memory loss, rash and vomiting. [1]

Overdose

Signs of procyclidine overdose are those of an anticholinergic and include confusion, agitation and sleeplessness that can last up to or more than 24 hours. Pupils become dilated and unreactive to light. Tachycardia (fast heart beat), as well as auditory and visual hallucinations have also been reported.

Other known symptoms of overdose are: clumsiness or unsteadiness, being severely drowsy, having a severely dry mouth, nose, or throat, having an altered mood or other mental changes, seizures, being short of breath or having troubled breathing, a dry and warm, flushed skin.

A suspected overdose with severe life-threatening symptoms should immediately be brought to medical attention, where reversal can be attempted with physostigmine administered intravenously or subcutaneously.

Pharmacology

Pharmacodynamics

Procyclidine is an anticholinergic.[2] It is specifically an antimuscarinic.[2] The drug acts as a non-selective antagonist of the muscarinic acetylcholine M1, M2, and M4 receptors, whereas its activities at the M3 and M5 receptors are reportedly unknown.[2]

Chemistry

Synthesis

Procyclidine synthesis:[3] U.S. patent 2826590

Procyclidine, 1-cyclohexyl-1-phenyl-3-pyrrolidinopropan-1-ol, is synthesized in exactly the same manner as was seen for trihexyphenidyl, except this time the linear synthesis begins with the preparation of 3-(1-pyrrolidino)propiophenone.

Procyclidine synthesis 2[4]

In an interesting variation, the ketone is first reacted with phenylmagnesium bromide. Catalytic hydrogenation of the carbinol thus obtained can be stopped after the reduction of only one aromatic ring.

Procyclidine synthesis (Morton)
Procyclidine synthesis (Morton)

Morton method:[5][6] The Reformatsky reaction between Cyclohexyl phenyl ketone (BzCy) [712-50-5] (1) and Ethyl Bromoacetate [105-36-2] (2) gives ethyl 3-cyclohexyl-3-hydroxy-3-phenylpropanoate, PC12565684 (3). The reduction of the ester gives 1-cyclohexyl-1-phenylpropane-1,3-diol, PC13841193 (4). FGI of the primary alcohol to the Tosyl leaving group gives 3-Cyclohexyl-3-hydroxy-3-phenylpropyl 4-methylbenzenesulfonate [102473-43-8] (5). Alkylation with pyrrolidine [123-75-1] completes the synthesis of procyclidine.

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Procyclidine Hydrochloride". National Institute for Health and Care Excellence. Retrieved 2020-07-06.
  2. ^ a b c Page Module:Citation/CS1/styles.css has no content.Lakstygal AM, Kolesnikova TO, Khatsko SL, Zabegalov KN, Volgin AD, Demin KA, Shevyrin VA, Wappler-Guzzetta EA, Kalueff AV (May 2019). "DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens". ACS Chem Neurosci. 10 (5): 2144–2159. doi:10.1021/acschemneuro.8b00615. PMID 30566832.
  3. ^ Page Template:Citation/styles.css has no content.DE 1084734, Jassmann, Edgar & Pfanz, Hermann, "Verfahren zur Herstellung von tertiäeren Aminoalkoholen [Process for the preparation of tertiary amino alcohols]", published Script error: No such module "auto date formatter"., assigned to VEB Fahlberg-List Chemische und Pharmazeutische Fabriken 
  4. ^ Page Module:Citation/CS1/styles.css has no content.Adamson DW, Barrett PA, Wilkinson S (1951). "11. Aminoalkyl tertiary carbinols and derived products. Part IV. Spasmolytics. Phenyl- and cyclohexylphenyl-carbinols". Journal of the Chemical Society (Resumed): 52. doi:10.1039/jr9510000052.
  5. ^ Harfenist Morton, Ernest G Magnien, U.S. patent 2842115 (1958 to Burroughs Wellcome Co).
  6. ^ , GB773748 (1957 to Wellcome Foundation Ltd).

Further reading

Template:Antiparkinson Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Muscarinic acetylcholine receptor modulators